Callodine Capital Management LP Buys 20,000 Shares of Sanofi (NASDAQ:SNY)

Callodine Capital Management LP lifted its position in Sanofi (NASDAQ:SNY - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 384,189 shares of the company's stock after acquiring an additional 20,000 shares during the quarter. Sanofi accounts for approximately 3.8% of Callodine Capital Management LP's holdings, making the stock its 8th largest position. Callodine Capital Management LP's holdings in Sanofi were worth $18,529,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in SNY. Altshuler Shaham Ltd acquired a new position in Sanofi in the fourth quarter worth $482,000. NewEdge Advisors LLC boosted its holdings in shares of Sanofi by 19.3% in the 4th quarter. NewEdge Advisors LLC now owns 36,796 shares of the company's stock valued at $1,775,000 after buying an additional 5,958 shares during the period. Evergreen Capital Management LLC boosted its holdings in shares of Sanofi by 14.6% in the 4th quarter. Evergreen Capital Management LLC now owns 17,099 shares of the company's stock valued at $825,000 after buying an additional 2,181 shares during the period. Guggenheim Capital LLC bought a new stake in shares of Sanofi during the 4th quarter valued at about $295,000. Finally, Causeway Capital Management LLC raised its stake in Sanofi by 38.8% during the fourth quarter. Causeway Capital Management LLC now owns 690,436 shares of the company's stock worth $33,300,000 after acquiring an additional 192,954 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Price Performance

Sanofi stock traded up $1.09 during trading hours on Wednesday, hitting $52.94. 1,452,469 shares of the company traded hands, compared to its average volume of 2,357,618. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market cap of $133.74 billion, a P/E ratio of 21.26, a P/E/G ratio of 1.01 and a beta of 0.57. The firm's 50-day simple moving average is $54.61 and its two-hundred day simple moving average is $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's dividend payout ratio is currently 64.26%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.